UPDATE -- Axiom Presents "Rare Disease Studies – Using technology to expand the opportunities of enrollment" at Clinical Trials in Rare Diseases Conference 2021 Print E-mail
By GLOBE NEWSWIRE   
Tuesday, 14 September 2021 05:19

TORONTO, Sept. 14, 2021 (GLOBE NEWSWIRE)

TORONTO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at the Clinical Trials in Rare Diseases Conference on September 14th, 2021. With over 40 solution providers gathering at the virtual meeting, the conference provides the industry leaders with an excellent opportunity to reconnect with current business partners and explore innovative technologies for improving Rare Diseases clinical trials.

Presenting "Rare Disease Studies – Using technology to expand the opportunities of enrollment," Axiom's Brian Dempster, Senior Director of Global Clinical Management and Dawn Weagle, Associate Director of eClinical and Project Management, will be sharing their insights on September 14th at 1:00 PM EDT. Their session will identify enrollment challenges and opportunities for Rare Disease Studies, demonstrate technology solutions that can create engagement, and present how a unified platform and centralized data can streamline the process.

"Patient recruitment has been a major challenging issue in rare disease clinical trials since the patient population are very few and often fragile," shared Weagle. "At the same time, rare disease studies often involve critical data from such small number of subjects across EDC, ePRO, RTSM, and lab data, highlight the challenges that study management might face. Additionally, access to real-time study status and reports imposes the challenges for solution providers to innovate data-driven studies."

“Subject engagement is the key in improving the quality of rare disease clinical trials. At Axiom, Fusion’s eClinical Suite, which delivers a unified, central management and reporting platform  which enables study management to oversee study data, ops, compliance and patient retention. Fusion brings CRA, site, and subject engagement together so every aspect of the rare disease clinical trials can be monitored and analyzed in real-time.”

To register for this event, please visit: https://www.eventsonlineregister.com/tc-events/clinical-trials-in-rare-diseases/

Learn more about Axiom’s Fusion eClinical Suite: https://www.axiommetrics.com/fusion-eclinical-suite/

About Axiom Real-Time Metrics

Axiom is celebrating its 20th anniversary after delivering hundreds of studies in dozens of countries. Since 2001, Axiom has delivered data-driven, powerful and cost-effective eClinical Solutions and Services dedicated to small-to-medium life science companies. Fusion eClinical Suite is the most adaptable, unified platform that serves as the Connected Hub for all your Clinical Trial and operational data and reporting. Choose from over 15 fully integrated modules on a single platform: EDC, DM, RTSM/IWRS, CTMS, Inventory Management, ePRO, eConsent, Patient Portal, AE/SAE Tracking, Safety Database, Central/Local Lab, Imaging Management, eTMF, and 24/7 Project and Clinical Data Reporting. We are an embedded partner dedicated to the success of your study, offering managed services such as: Data Management, On-Demand Data Analytics, Biostatistics, Clinical Management, eTMF Management and Pharmacovigilance.

For more information, please visit https://www.axiommetrics.com

PR Contact
Faye Cai
[email protected]
+1 437.522.8497

 


Primary Logo




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter